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Abstract
We analyzed genetic diversity and phylogenetic relationships among 124 HIV-1 and 19 HIV-2 strains in sera collected in 1986
from patients of the state hospital in Ouagadougou, Burkina Faso. Phylogenetic analysis of the HIV-1 env gp41 region of 65
sequences characterized 37 (56.9%) as CRF06_cpx strains, 25 (38.5%) as CRF02_AG, 2 (3.1%) as CRF09_cpx, and 1 (1.5%) as
subtype A. Similarly, phylogenetic analysis of the protease (PR) gene region of 73 sequences identified 52 (71.2%) as
CRF06_cpx, 15 (20.5%) as CRF02_AG, 5 (6.8%) as subtype A, and 1 (1.4%) was a unique strain that clustered along the B/D
lineage but basal to the node connecting the two lineages. HIV-2 PR or integrase (INT) groups A (n = 17 [89.5%]) and B (n = 2
[10.5%]) were found in both monotypic (n = 11) and heterotypic HIV-1/HIV-2 (n = 8) infections, with few HIV-2 group B
infections. Based on limited available sampling, evidence suggests two recombinant viruses, CRF06_cpx and CRF02_AG,
appear to have driven the beginning of the mid-1980s HIV-1 epidemic in Burkina Faso.
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Introduction
Acquired immunodeficiency syndrome (AIDS) is caused by two
genetically distinct types of human immunodeficiency virus (HIV),
HIV type 1 (HIV-1) and HIV type 2 (HIV-2). HIV-1 consists of
four major groups, M, N, O and P, each resulting from separate
cross-species transmissions from chimpanzees or gorillas to
humans [1–5]. Within the Group M viruses, phylogenetic analysis
has identified 12 subtypes and sub-subtypes (A1, A2, A3, B, C, D,
F1, F2, G, H, J and K), at least 57 circulating recombinant forms
(CRFs), and innumerable unique recombinant forms, which
encompass the majority of HIV-1 infections worldwide [6]. The
level of infections with group O viruses has remained very low and
they are found mostly in West-Central Africa [7,8]. Currently,
very few cases of HIV-1 groups N and P have been identified, all
in persons from Cameroon [4,9–14].
Similarly, HIV-2, which is the result of 8 separate cross-species
infections from sooty mangabey monkeys to humans, has been
classified into genetically distinct groups designated A to H and are
found primarily in West African countries, such as Guinea-Bissau,
Senegal, Ivory Coast, Sierra Leone, Ghana, Mali, and The
Gambia [15–18], but has spread to other non-African countries
[19,20]. HIV-2 group A is most prevalent, followed by group B.
HIV-2 groups C-H are rare [21,22].
Although HIV-1 and HIV-2 seroreactivity was first reported in
sub-Saharan African countries in the mid-1980s [23–25], little
genetic characterization has been done on those early HIV strains.
Phylogenetic characterization of HIV sequences remains a
powerful tool for tracking the evolution and distribution of HIV
worldwide. Of critical importance to our understanding the
evolution of the HIV pandemic is having access to samples from
early in the epidemic, especially from West and Central Africa,
which are the epicenters of the HIV-2 and HIV-1 epidemics,
respectively [17,26,27]. The earliest known HIV-1 sequence
(ZR59) came from a 1959 HIV-1 seropositive plasma sample
from Zaire, now called the Democratic Republic of Congo (DRC).
Phylogenetic analysis of gag, pol, and env genes confirmed it as an
HIV-1 group M virus and placed it basal to the node connecting
the subtype B and D lineages [28]. The second earliest known
HIV sequence was found in a 1960 lymph node biopsy specimen
obtained from an adult female in Kinshasa, Zaire (DRC60), and
was phylogenetically characterized as HIV-1 group M, subtype A
in the gag, pol and env gene regions [29]. Finding viruses from two
different HIV-1 subtypes, suggested that significant viral diversi-
fication had already taken place by 1960 [29]. Next, 56 samples
from Kinshasa, Zaire, collected in the mid-1980s, demonstrated
the presence of all the HIV-1 group M subtypes, except B, along
with circulating recombinant form (CRF) 01 (CRF01_AE), and
many unique recombinant strains [27].
Between 1985-1987 the HIV-2 strains ROD, BEN and ST,
isolated from patients with AIDS from Cape Verde, Mali and
Senegal, respectively, phylogenetically clustered with HIV-2 group
A reference strains [30-32], while the HIV-2 strains GH-2, D205
and UC1 (1986–1988) recovered from AIDS patients in Ghana
and Ivory Coast, respectively, clustered with HIV-2 group B
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[32,33–35]. To date, no HIV-2 subtypes have been described for
any of the HIV-2 groups.
Early studies on serum specimens from Burkina Faso, collected
between 1985–1987, showed an HIV seroprevalence of 1.7%,
1.8%, 4.5% and 14.6% among pregnant women, prisoners,
hospital patients and prostitutes, respectively [36]. A study from
1994 showed the HIV prevalence in female sex workers to be as
high as 58.2% [37]. The first HIV-1 genetic subtype described
from Burkina Faso was in a specimen collected in 1996 [38,39].
Phylogenetic analysis of the full genome sequence classified the
HIV isolate, BFP90, as a complex recombinant, CRF06_cpx
involving recombination between at least 4 HIV-1 subtypes: A, G,
J and K [38,39,40]. Thereafter, additional studies on specimens
collected in 1996, 2000, 2001, 2003, and 2004 have confirmed
CRF06_cpx to be the predominant strain in Burkina Faso,
followed by CRF02_AG, and the less prevalent subtypes A, A3, G,
F1, H and CRF09-cpx [41–43]. In other West and West-Central
African countries, such as in Senegal, Ivory Coast, Nigeria,
Gabon, Cameroon, where multiple subtypes and CRFs co-
circulate, more recent samplings have reported their predominant
HIV-1 strain as CRF02_AG [44–46].
In this study we have sequenced and performed phylogenetic
analysis on HIV strains from specimens collected in 1986 in the
West African city of Ouagadougou, Burkina Faso, in order to
characterize the viruses that may have initiated the early epidemic




We received 849 remnant and anonymized serum samples
collected in 1986 from patients attending the state hospital in
Ouagadougou, the capital of Burkina Faso in West Africa. The
amount of the serum samples we received was very small, ranging
from 100 ml to about 250 ml. Since both HIV-1 and HIV-2 are
found in West Africa, all sera were tested by two separate whole
viral lysate EIA assays to detect antibodies to HIV-1 and HIV-2
(Genetic Systems, Redmond, WA, USA). To confirm HIV type,
EIA reactive specimens were tested with INNO-LIA HIV-1/2
(INNOGENETICS, Ghent, Belgium), which has synthetic pep-
tides recognizing antibodies to HIV-1 p17, p24, p31, gp41, and
gp120 proteins, and to HIV-2 gp36 and gp105 proteins. Western
blot was performed on some samples, however, the discrimination
between HIV-1 and HIV-2 was based on INNO-LIA HIV-1/2
results as previously described [47,48].
Ethical Approval
The initial HIV prevalence survey samples were consented to at
the time of blood draw, but there was no formal IRB in Burkina
Faso in 1986 and no written informed consent retained.
Permission for the survey and specimen collection was granted
by the Ministry of Health of Burkina Faso. For purposes of the
genetic studies reported here, the archived specimens were
received unlinked and anonymized and oversight of their analysis
fell under the Global Monitoring for Variants Strains of HIV
protocol #1367 approved by the CDC Institutional Review
Board.
RNA Extraction, Amplification and Sequencing
Extraction of RNA from all INNO-LIA positive sera was done
using the NucliSens nucleic acid manual or automated protocols
(Organon Teknika, Boxtel, the Netherlands). Conditions for RT-
PCR and secondary DNA PCR amplifications (RT-PCR/PCR)
and the sets of primers for HIV env gp41 region, PR, and INT
amplifications have been described previously: HIV-1 env gp41
(outside: gp40F1/gp41R1 and nested: gp46F2/gp47R2 or
gp48R2) [49]; HIV-1 PR (outside: DP10F/DP11R and nested:
DP16F/DP17R) [50,51], HIV-2 PR (outside: DP20F/DP21R and
nested: DP26aF/DP27R) [52]; and HIV-2/SIV INT (outside:
INT-F1/INT-R1 and nested: INT-F2/INT-R2) [53]. PCR-
amplified products were purified with the QIAquick PCR
Purification Kit (Qiagen, Valencia, CA USA) and directly
sequenced with both forward and reverse nested PCR primers
on an automated DNA sequencer (ABI model 377; Applied
Biosystems Inc., Foster City, CA).
Characterization of Specimens
HIV sequences from INNO-LIA positive sera were subjected to
RT-PCR/PCR amplification of different regions of the HIV
genome. First, HIV-1 seropositive specimens were amplified using
Table 1. Summary of distribution of HIV-1 (env gp41, PR) and HIV-2 (PR and INT) gene sequences.
HIV-1 Only HIV-2 Only HIV-1 and HIV-2
Viruses *PR *gp41 Viruses *PR *INT Viruses *HIV-1 PR *HIV-1 gp41 *HIV-2 PR *HIV-2 INT
n = 11 CRF02 Neg n = 10 A Neg n = 1 CRF02 Neg A Neg
n = 39 CRF06 Neg n = 1 Neg B n = 2 CRF06 Neg A Neg
n = 4 A Neg n = 1 A Neg B Neg
n = 1 B/D Neg n = 1 CRF06 A Neg
n = 20 Neg CRF02 n = 3 CRF06 CRF06 A Neg
n = 27 Neg CRF06
n = 2 Neg CRF09
n = 1 Neg A
n = 3 CRF02 CRF02
n = 6 CRF06 CRF06
n = 2 CRF06 CRF02
CRF, denotes circulating recombinant forms; * denotes gene regions where RT-PCR amplification was attempted; PR, protease; INT, denotes Integrase; gp41, envelope
glycoprotein 41. Neg indicates no amplifiable PCR product.
doi:10.1371/journal.pone.0092423.t001
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env gp41 primers that allow amplification of HIV-1 groups M, N,
and O and SIVcpz within a 366-bp fragment [49]. Samples were
further screened for HIV-1 using PR primers known to amplify the
entire 297-bp PR gene of group M subtypes A-K in field samples
with a high efficiency [54,55]. HIV-2 seropositive specimens were
amplified with HIV-2 type-specific PR primers that allow
identification of at least the two major groups, A and B [52].
The HIV-2 PCR samples from this collection were further
screened for HIV-2 with pol-INT primers.
Specimens showing INNO-LIA HIV-1/HIV-2 heterotypic
seroreactivity were submitted to separate amplifications with
HIV-1 and HIV-2 PR primers, which are type specific and permit
selective PCR amplification of HIV-1 and HIV-2 strains from
mixed HIV-1/HIV-2 infections [56]. These samples were
additionally screened for the presence of HIV-1 with gp41
primers and for HIV-2 with pol-INT primers [53]. Sequencing
of two different gene regions, especially from opposite ends of the
genome, might increase the likelihood of detecting potential HIV-
1 intersubtype recombinants. Since our serum samples were more
than 20 years old and the HIV RNA was likely degraded, we
selected both the HIV-1 gp41 and PR gene regions and the HIV-2
PR and INT genes for initial amplification attempts because they
are reasonably conserved genes and fairly short gene regions.
Phylogenetic Analysis
The derived HIV-1 and HIV-2 DNA sequences were aligned
using CLUSTAL W1.83 multiple-sequence alignment program
included in the GeneStudio package, which provides the interface
to phylogenetic programs on a PC workstation [57]. Alignments
included known HIV-1 or HIV-2 sequences extracted from the
Los Alamos Laboratory HIV Sequence database [58], represent-
ing the different genetic subtypes and the CRFs documented in
West Africa. Phylogenetic analysis was performed by the neighbor
joining method, with the nucleotide distance calculated by
Kimura’s two-parameter model included in the PHYLIP package
(version 3.5c) [59] with and without bootstrapping. SIVcpz
sequences were used as outgroups. It was further verified with
Maximum Likelihood method using FastDNAml program (http://
www.genestudio.com).
Genetic Distance Analysis
Subtype and CRF designations were determined from phylo-
genetic analysis, and sequences were input into the MEGA
program, version 2.0 [60] to calculate the means of the pair-wise
genetic differences among each subtype and CRF. Values for the
genetic differences between sequences were evaluated based on the
distance index that was created from the nucleotide alignment [61]
Sequence Data
The sequences obtained in this study have been deposited in
GenBank under the following accession numbers: AY640416-
AY640433 for HIV-2 Protease; AY645781-AY645795 for HIV-1
Protease CRF02; AY662958-AY662982 for HIV-1 env gp41
CRF02; AY928421-AY928457 for HIV-1 env gp41 CRF06.
Results
Seroreactivity and RT-PCR Amplification
Of the 849 1986 Burkina Faso specimens from hospitalized
patients, 172 (20.3%) were confirmed to be HIV-1 and/or HIV-2
seropositive by the INNO-LIA HIV Line assay. From the 172
seropositive samples, 124 (72.1%) were only HIV-1 RT-PCR/
PCR amplifiable; 51 (41.1%) were amplified by gp41 primers, 59
(47.6%) by PR primers and 14 (11.3%) were amplified by both
gp41 and PR primers (Table 1). Monotypic HIV-2 was amplified
from 11 seropositive samples, 10 (90.9%) in the PR region, and 1
(9.1%) additional sample was amplified in the HIV-2 INT region.
Both HIV-1 and HIV-2 were amplified from 8 samples: 7 HIV-1
PR genes and 8 HIV-1 gp41 genes were amplified and all 8 HIV-2
strains were amplified by HIV-2 PR primers.
Phylogenetic Analysis of Early Sequences
Phylogenetic analysis of the 65 HIV-1 gp41 sequences from
monotypic and heterotypic infections demonstrated that 37
(56.9%) were subtype G in that region, but further stongly
subclustered with CRF06_cpx reference sequences; likewise, 25
(38.5%) clustered with subtype A sequences yet further subclus-
tered with CRF02_AG reference strains (Figure 1A). Two (3.1%)
were also subtype A but further subclustered with CRF09_cpx
reference strains, and 1 (1.5%) clustered with subtype A reference
sequences without any further subclustering. Similarly, phyloge-
netic analysis of the PR gene region of 73 sequences revealed 52
(71.2%) strongly subclustered with CRF06_cpx reference sequenc-
es, 15 (20.5%) subclustered with CRF02_AG, 5 (6.8%) closely
related sequences clustered with subtype A sequences and 1 (1.4%)
was a unique strain that clustered within the B/D lineage but basal
to the node connecting the two (Figure 1B). Parallel analysis of
HIV-1 PR and env gp41 gene regions, for the 14 strains with
sequences available from both genes, revealed CRF concordance
in 12 (85.7%) viruses, with 3 CRF02_AG(PR)/CRF02_AG(gp41)
and 9 CRF06_cpx(PR)/CRF06_cpx(gp41). Of those with discor-
dance between the two gene regions, 2 had mosaic patterns of
CRF06_cpx(PR)/CRF02_AG(gp41) (Table 1), demonstrating
further recombination occurring between the two prevalent
recombinant viruses. The distribution of HIV-1 subtypes, recom-
binants, and dual infections is shown in Table 1. One limitation of
our study is that we were only able to amplify fairly short gene
regions due to small serum volumes and degradation to the HIV
RNA since collection in the mid-1980s. While we tried to amplify
both HIV-1 gp41 and PR for HIV-1 serologically determined
homotypic infections, HIV-2 PR and INT for HIV-2 homotypic
infections, and both for HIV-1/HIV-2 heterotypic infections, for
most samples we only had success with one of the two gene
regions.
Phylogenetic analysis of 19 HIV-2 PR sequences from
monotypic and heterotypic infections classified 17 sequences as
group A (89.5%) and 2 as group B (10.5%) (Figure 2), with one of
the group B being an INT sequence (Table 1). HIV-2 group A
sequences were identified in all 10 HIV-2 monotypic infections.
From the 8 HIV-1/HIV-2 heterotypic infections, HIV-1 strains
were represented by 2 CRF06_cpx(PR) (25%), 1 CRF02_AG(PR)
Figure 1. Neighbor-joining tree of HIV-1 env gp41 (n = 65) and protease (73) sequences collected in 1986. The Burkino Faso sequences
are identified by the prefix, BF. Sequences from mixed HIV-1/HIV-2 infections are highlighted in gray. The reference HIV-1 group M and CRF
sequences, respectively, have prefixes A, B, C, D, F1, F2, G, H, J, K, and potential L to denote the subtype or sub-subtype, or number indicating which
CRF they represent, i.e., 1 for CRF01, 2 for CRF02, etc. The position of the outgroup (SIV-cpz sequence) is not shown. The numbers on nodal branches
represent the bootstrap values (out of 100 replicates); only values 68% or greater are shown. The scale bar indicates an evolutionary distance of 0.1
nucleotides per site. Vertical distances are for clarity only.
doi:10.1371/journal.pone.0092423.g001
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(12.5%), 1 CRF06_cpx(gp41) (12.5%), 3 CRF06_cpx(PR)/
CRF06_cpx(gp41) (37.5%) and 1 subtype A in PR (12.5%) (Table
1). From those 8 heterotypic HIV-1/HIV-2 infections, HIV-2
group A was present in 7 (87.5%) and group B in 1 (12.5%).
Genetic Distance Analysis
We found the mean nucleotide distance among all 52 Burkina
Faso HIV-1 CRF06_cpx(PR) sequences was 1.1% (range 0.1–
4.1%) (Table 2). Similarly, there was a limited nucleotide
divergence with a mean of 1.8% (range 0.3–3.8%) for the 15
CRF02_AG(PR) sequences (Table 2). Also, low genetic distances
were observed for the 37 CRF06_cpx(gp41) sequences with a
mean of 2.0% (range 0.3–6.3%), 25 CRF02_AG(gp41) with a
mean of 3.5% (range 0.8–7.7%), and 2 CRF09_cpx (mean 0.3%)
(Table 2).
Genetic distance analysis of the 17 group A HIV-2 PR
sequences revealed a broad diversity (mean 6.2%, 0.3–12.8%)
(Table 2). Eleven of the 17 HIV-2 PR group A sequences
phylogenetically clustered into 2 distinct subgroups supported by
high bootstrap value of 93% and 99%, respectively (Figure 2).
Pairwise nucleotide divergence was small among sequences within
these 2 groups: mean 0.8%, range 0.3–2.3% for group #1 and
mean 1.1%, range 0.3–3.0% for group #2 (Table 2). Pairwise
analysis of the remaining 6 unrelated HIV-2 sequences showed a
relatively high range (mean 6.1%, range 2.0–12.8%) of nucleotide
diversity due to either a long existence of HIV-2 strains in Burkina
Faso or the separate introduction of these variants into the
country.
Discussion
A unique set of historical serum samples collected in 1986 from
Burkina Faso provided us the opportunity to determine the types
and distribution of HIV that were present in the early years of the
epidemic in that country. Based on two gene regions, PR and env
gp41 of HIV-1 and PR or INT of HIV-2, our results showed that
recombinant viruses were co-circulating early in the epidemic with
the predominant strain being CRF06_cpx, a complex recombi-
nant virus consisting of genomic regions from subtypes A, G, J,
and K. CRF02_AG was the next major strain, followed by subtype
A and CRF09_cpx, another complex recombinant virus, as minor
strains. In addition, HIV-1 and HIV-2 heterotypic and HIV-2
monotypic infections were also present, with HIV-2 group A
present in the majority of these infections.
Phylogenetic analysis of nucleotide sequences showed that the
early 1986 HIV-1 epidemic in Burkina Faso was driven by
recombinant viruses, with CRF06_cpx and CRF02_AG causing
the majority of infections. Although these samples came from one
hospital in Quagadougou, almost thirty years later the same CRFs
are still predominant and co-circulating today and causing
infections in Burkina Faso, with no significant change in
proportion between CRF06_cpx and CRF02_AG [62,63]; thus,
strongly suggesting the same strains that initiated the early
epidemic. Similarly, Kalish et al [24] found the distribution of
HIV-1 strains in Kinshasa, Zaire from 1984 through 1986 were
composed of CRF01_AE, unique recombinant viruses, unclassi-
fiable strains, and all the group M subtypes but B. Other
researchers found almost 20 years later, that the type and
proportion of the Kinshasa subtypes and recombinant viruses
were strikingly similar [26,64].
Some of the earliest known samples of HIV infection (ZR59 and
DRC60) were traced back to Kinshasa, Zaire [28,29]. Although
Central Africa appears to be the epicenter of the HIV-1 pandemic,
CRF02_AG and CRF06 were not reported in Kinshasa until
2004. Following the first report of CRF06_cpx in a Burkina Faso
specimen (BFP90) in 1996 [38,41] and later in Mali in 1999 [39],
CRF06_cpx viruses have since been documented in other West
African countries, including Senegal, Mali, Ivory Coast, Niger and
Nigeria [40,65]. It is unclear where CRF06_cpx arose. Some have
speculated that it originated in Burkina Faso because of the early
predominance of CRF06_cpx in the country [41]. However,
CRF06_cpx is a complex recombinant with portions of HIV-1
subtypes A, G, J, and K. Since subtypes J and K have not been
reported in West Africa, especially so early in the epidemic, it does
not seem likely that it could have arisen from multiple
recombination events in Burkina Faso. A more plausible
explanation is that it may have evolved in West-Central Africa,
the epicenter of the HIV pandemic, and radiated to the west.
Alternately, the first recombination events could have taken place
in West-Central Africa, for instance between viruses from subtypes
J and K, and additional recombination events took place when
people with these infections traveled to the west where subtypes A
and G were commonly reported. Since we only had PR or gp41
sequences, and both of these gene regions for CRF06-cpx are
subtype G, another interesting possibility might be that these
viruses could represent parental subtype G strains from which the
CRF06 arose. However, as we state above, we do not believe that
CRF06 originated in West Africa, since viruses of subtypes J and K
were only found in Central Africa in the mid-1980s [27] and are
still unreported in West Africa. Furthermore, recombination had
to occur multiple times to generate the CRF06 virus. The very
high genetic relatedness of all our early CRF06 viruses in Burkina
Figure 2. Neighbor-joining tree of 18 HIV-2protease sequences; the prefix BF represents sequences recovered from Burkina Faso
patients in 1986. For comparison, 7 1980s sequences from Ivory Coast were included in the tree and contain the prefixes IC. Highlighted sequences
in gray were from mixed HIV-1/HIV-2 infections; the remainders were from monotypic HIV-2 infections; groups #1 and #2 within subtype A
represent distinct subclusters of closely related sequences. Viruses from sooty mangabeys are shown (SIVsm). The position of the outgroup (SIV-cpz
sequence) is not shown. The number on the node indicates the bootstrap value; only values 68% or greater are shown. The scale bar indicates an
evolutionary distance of 0.1 nucleotides per site. Vertical distances are for clarity only.
doi:10.1371/journal.pone.0092423.g002
Table 2. Genetic distances within HIV subtypes and CRFs.
Gene
Region n Subtype Distance (%)
Mean Range
HIV-1 PR 15 CRF02 1.8 0.3–3.8
52 CRF06 1.1 0.1–4.1
HIV-1 gp41 25 CRF02 3.5 0.8–7.7
37 CRF06 2 0.3–6.3
HIV-2 PR 17 A 6.2 0.3–12.8
HIV-2 PR group
#1
5 A 0.8 0.3–2.3
HIV-2 PR group
#2
6 A 1.1 0.3–3.0
CRF, circulating recombinant forms.
doi:10.1371/journal.pone.0092423.t002
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Faso, and their close evolutionary relationship to CRF06 reference
sequences, supports the conclusion that CRF06 was most likely
introduced into Burkina Faso a couple years before our sampling
in 1986. Finally, CRF06 and CRF02 are currently co-circulating
in Burkina Faso in roughly the same proportions as we found in
1986 [62,63].
CRF02-AG was first identified in West Africa between 1989
and 1991 [66,67], and soon became the prominent strain
throughout much of West and West Central African countries,
including Nigeria, Cameroon, Senegal, and Cote d’Ivoire [65,68–
72]. While some investigators have suggested that recombinant
viruses have the potential to be more pathogenic, more
transmissible, or more biologically fit [73–78], it still remains to
be proven that recombinant viruses have a selective advantage
[79]. West Africa in the early 1980s was not yet experiencing an
HIV-1 epidemic, so it was easy for newly introduced HIV-1 strains
to become established within high-risk groups and then radiate out
into the rest of the population. It is interesting, though, that the
two strains that appear to have driven the 1986 HIV-1 epidemic in
Burkina Faso were the recombinant viruses CRF06_cpx and
CRF02_AG.
While the range of intra-subtype diversity was high in Kinshasa,
Zaire in 1984-1986 [27], the intra-CRF diversity was low among
1986 HIV-1 PR and gp41gene sequences from Burkina Faso,
suggesting that this was a much newer epidemic. In Zaire, during
the same time period, the mean range of intra-CRF and intra-
subtype diversity spanned 9.6% through 19.7% in the env C2V3C3
gene region, yet the env gp41 genetic distances for CRF06 and
CRF02 showed only an average nucleotide difference of 3.5% and
2.0%, respectively. While the gp41 region is more conserved than
the C2V3C3 region of the envelope, it does not explain the huge
differences seen between the Kinshasa and Ouagadougou
divergence among sequences from each city. The small amount
of genetic differences among the viruses within CRF06_cpx and
CRF02_AG suggest that they were recently introduced into
Burkina Faso as founder viruses, not long before their sampling in
1986. Since the genetic divergence is larger for CRF06_cpx in
both gene regions analyzed, it suggests that CRF02_AG may have
entered Burkina Faso as a founder virus shortly after CRF06_cpx.
A somewhat similar finding of low diversity among two founder
viruses, CRF01_AE and subtype B’ was observed from specimens
collected shortly after their introduction into Thailand [80]. Thai
national serosurveys allowed researchers to conclude that there
were two separate introductions of subtype B’ and CRF01_AE by
parenteral and sexual risk factors, respectively, approximately one
year apart. Unfortunately, we do not have any data about risk
factors that might have helped us explain how these recombinant
viruses entered Burkina Faso, but they do appear to be sequential
introductions occurring within a couple years of each other.
Although there are at least 8 HIV-2 groups [15–17], only A and
B have become endemic throughout West Africa, with group A
being the dominant strain, except in Cote d’Ivoire, where HIV-2
group B is prevalent [81–83]. In our study of HIV strains in
Burkina Faso, we found monotypic HIV-1 or HIV-2 infections as
well as heterotypic HIV-1 and HIV-2 infections. Similar to what
has been observed previously in West Africa, HIV-2 group A was
predominant in Burkina Faso whether in HIV-2 monotypic or
HIV-1/HIV-2 heterotypic infections.
We found the mean PR genetic distance among Burkina Faso
HIV-2 group A viruses was 6.2%, which is considerably more
divergent than HIV-1 PR for CRF02_AG and CRF06_cpx (1.8%
and 1.0%, respectively). Since HIV-1 replicates faster and diverges
more quickly than HIV-2, this greater divergence of HIV-2 viruses
in Burkina Faso suggests that the introduction of HIV-2 could
have predated the introduction of HIV-1, which is consistent with
observations in other West African countries [84,85]. However,
another explanation for the higher diversity of HIV-2 group A
could be the separate introduction of divergent strains into
Burkina Faso, carried in from other West African countries where
HIV-2 was already endemic.
Analysis of HIV-2 phylogenetic trees from Burkina Faso showed
two strongly related sequence subclusters within group A. Each
subcluster defines groups of closely related sequences with very
short branch lengths and small nucleotide differences among
them. These clusters represent two founder group A viruses that
entered Burkina Faso and subsequently spread rapidly, most likely
due to the high-risk groups they entered. These types of
transmission networks contributed significantly to establishing
HIV-2 infections in Burkina Faso and throughout West Africa. In
addition, phylogenetic analysis demonstrated the sequences in
group #2 formed a strong monophyletic cluster (99% bootstrap
support) with the reference sequence NIHZ, which was originally
isolated in 1986 from Guinea Bissau [86]. Such a relationship
suggests that some of the HIV-2 strains found in Burkina Faso
might have their origins in Guinea Bissau, a country in West
Africa with one of the highest prevalences of HIV-2 infections [87]
or that NIHZ-like strains originated in Burkina Faso and helped
establish the HIV-2 epidemic in Guinea Bissau.
In summary, our results provide new and unique insights into
the HIV epidemic in West Africa during this early period in the
global pandemic. Based on sequences from only 138 HIV strains,
it appears that CRF02_AG and CRF06_cpx were founder viruses
that initiated the early HIV-1 epidemic in Burkina Faso. We also
provide characterization of early HIV-2 sequences and document
that while group A was predominant, both groups A and B
variants were found in both HIV-2 monotypic and mixed HIV-1/
HIV-2 infections. This information is critical for understanding
the newly emerging HIV epidemic in Burkina Faso and for
monitoring the dissemination and evolution of HIV-1 and HIV-2
strains in Burkina Faso, as well as throughout West Africa.
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superinfections in a cohort of commercial sex workers in Burkina Faso as
assessed by an autologous heteroduplex mobility procedure. AIDS 18: 1645–51.
43. Tebit DM, Ganame J, Sathiandee K, Nagabila Y, Coulibaly B, et al. (2006)
Diversity of HIV in rural Burkina Faso. J Acquir Immune Defic Syndr 43: 144–
52.
44. Nkengasong JN, Luo CC, Abouya L, Pieniazek D, Maurice C, et al. (2000)
Distribution of HIV-1 subtypes among HIV-seropositive patients in the interior
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